Leuthold Group LLC Takes $4.73 Million Position in Gilead Sciences, Inc. $GILD

Leuthold Group LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 42,636 shares of the biopharmaceutical company’s stock, valued at approximately $4,733,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $2,150,268,000. Ameriprise Financial Inc. grew its stake in shares of Gilead Sciences by 397.6% in the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after acquiring an additional 5,392,191 shares in the last quarter. Invesco Ltd. grew its stake in shares of Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after acquiring an additional 3,394,330 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Gilead Sciences by 164.4% during the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after acquiring an additional 2,169,266 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Gilead Sciences by 1.6% in the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after acquiring an additional 1,893,401 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of analyst reports. Royal Bank Of Canada increased their price target on Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a research report on Wednesday. Morgan Stanley raised their target price on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday. Truist Financial lifted their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Wednesday. Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Wall Street Zen lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Twenty-four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $146.44.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 beat on top and bottom line: Gilead reported Q4 EPS of $1.86 vs. consensus ~$1.83 and revenue roughly $7.9B, powered by HIV and liver‑disease franchises — the core beat is the primary near‑term driver of the rally. Gilead quarterly results beat Wall Street estimates
• Positive Sentiment: Multiple analyst upgrades/price‑target raises: Banks including Morgan Stanley, JPMorgan, Wells Fargo, Needham and others bumped targets (some to $160–$177+), reinforcing buy/overweight sentiment and supporting the stock pop. Morgan Stanley raises price target
• Positive Sentiment: Yescarta label expansion and pipeline momentum: Positive commentary about CAR‑T (Yescarta) label expansion and new HIV options (Yeztugo) adds optionality to growth expectations. Yescarta label expansion and dividend growth
• Positive Sentiment: Dividend increase: Board raised the quarterly payout to $0.82 (3.8% increase), supporting income investors and reducing equity downside for dividend‑focused holders. Dividend announcement
• Neutral Sentiment: Investor commentary and transcripts: Earnings call and slides are available for detail on unit trends and margin commentary — useful for modeling but not an immediate directional driver. Earnings call transcript
• Neutral Sentiment: Short‑interest items in recent filings show no meaningful or reliable signal (reported zero/odd values), so ignore those as noise.
• Negative Sentiment: FY‑2026 guidance came in slightly light: Gilead set EPS guidance of $8.45–$8.85 and revenue guidance ~$29.6–$30.0B, marginally below consensus (~$30.1B / ~$8.69 EPS), which caused an initial after‑hours pullback and remains the main near‑term risk to sustaining the rally. Guidance story
• Negative Sentiment: Some cautious analyst views remain: A few firms (e.g., RBC with a lower PT) kept conservative ratings/targets, which could cap upside if other brokers re‑rate lower or fundamentals disappoint. Analyst notes (RBC)

Insiders Place Their Bets

In other news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director directly owned 8,920 shares in the company, valued at $1,101,620. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. The trade was a 1.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 319,391 shares of company stock worth $44,141,101. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $155.80 on Thursday. The business’s 50-day moving average price is $129.01 and its 200 day moving average price is $121.77. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The firm has a market cap of $193.30 billion, a P/E ratio of 23.01, a P/E/G ratio of 0.78 and a beta of 0.36. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 51.04%. Gilead Sciences’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. Gilead Sciences’s dividend payout ratio is presently 46.68%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.